Post-stroke Depression Increases Disability More Than 15% in Ischemic Stroke Survivors: A Case-Control Study.
antidepressants
depression
functional outcome
rehabilitation
stroke
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
04
2019
accepted:
09
08
2019
entrez:
12
9
2019
pubmed:
12
9
2019
medline:
12
9
2019
Statut:
epublish
Résumé
We performed a retrospective, case-control study in consecutive ischemic stroke patients admitted to our stroke rehabilitation unit. Patients were matched for severity of neurological impairment (evaluated with the Canadian Neurological Scale, CNS), age (difference within 1 year), and onset admission interval (difference within 3 days). Participants were divided into two subgroups according to the presence or absence of PSD. Aim was to assess the specific influence of post-stroke depression (PSD) and antidepressant treatment on both basal functional status and rehabilitation outcomes. All PSD patients were treated primarily with serotoninergic antidepressants (AD). The final sample included 280 patients with depression (out of 320 found in a whole case series of 993 ischemic patients, i.e., 32.25%) and 280 without depression. Forty patients with depression were excluded because they had a history of severe psychiatric illness or aphasia, with a severe comprehension deficit. On one hand, PSD patients obtained lower Barthel Index (BI) and Rivermead Mobility Index (RMI) scores at both admission and discharge, with minor effectiveness of rehabilitative treatment and longer length of stay; on the other hand, this group had a lower percentage of dropouts. Lastly, PSD patients showed a different functional outcome, based on their response to antidepressant therapy, that was significantly better in responders than in non-responders (13.13%). Our results confirm the unfavorable influence of PSD on functional outcome, despite pharmacological treatment.
Identifiants
pubmed: 31507525
doi: 10.3389/fneur.2019.00926
pmc: PMC6718567
doi:
Types de publication
Journal Article
Langues
eng
Pagination
926Références
Eur Neuropsychopharmacol. 1999 Jan;9(1-2):83-91
pubmed: 10082232
Arch Phys Med Rehabil. 1999 Jun;80(6):676-80
pubmed: 10378494
Clin Rehabil. 1999 Jun;13(3):268-72
pubmed: 10392654
Arch Phys Med Rehabil. 2000 Jun;81(6):695-700
pubmed: 10857508
Stroke. 2001 Jan;32(1):113-7
pubmed: 11136924
Eur J Neurol. 2001 Jul;8(4):315-9
pubmed: 11422427
J Neurol Neurosurg Psychiatry. 2001 Aug;71(2):258-61
pubmed: 11459907
J Clin Psychiatry. 2001;62 Suppl 16:5-9
pubmed: 11480882
Cerebrovasc Dis. 2001;12(3):264-71
pubmed: 11641594
Arch Phys Med Rehabil. 2001 Dec;82(12):1645-9
pubmed: 11733876
Stroke. 2002 Feb;33(2):542-7
pubmed: 11823667
Cerebrovasc Dis. 2003;15(1-2):98-105
pubmed: 12499718
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Md State Med J. 1965 Feb;14:61-5
pubmed: 14258950
Stroke. 2005 Apr;36(4):803-8
pubmed: 15761203
Cortex. 1978 Mar;14(1):41-9
pubmed: 16295108
J Rehabil Med. 2006 Mar;38(2):113-7
pubmed: 16546768
Lancet. 1991 Jun 22;337(8756):1521-6
pubmed: 1675378
J Neurol. 2006 May;253(5):556-62
pubmed: 16767539
J Clin Psychiatry. 2007 Jul;68(7):1062-70
pubmed: 17685743
Int Disabil Stud. 1991 Apr-Jun;13(2):50-4
pubmed: 1836787
CNS Drugs. 2009 Aug;23(8):627-47
pubmed: 19594193
Neurology. 2011 Mar 15;76(11):1000-5
pubmed: 21403112
Eur J Phys Rehabil Med. 2012 Sep;48(3):455-66
pubmed: 22522435
Stroke. 1990 Feb;21(2):241-6
pubmed: 2305399
Br J Psychiatry. 2013 Jan;202(1):14-21
pubmed: 23284148
Stroke. 2013 Mar;44(3):844-50
pubmed: 23362083
Stroke Res Treat. 2013;2013:862978
pubmed: 23533964
Stroke Res Treat. 2013;2013:846732
pubmed: 23555070
Int J Stroke. 2015 Aug;10(6):893-6
pubmed: 24165205
J Rehabil Med. 2014 Jun;46(6):514-9
pubmed: 24687167
Int J Stroke. 2014 Dec;9(8):1017-25
pubmed: 25117911
PLoS Med. 2014 Oct 14;11(10):e1001744
pubmed: 25314315
Neurology. 2014 Nov 25;83(22):2007-12
pubmed: 25355829
Neurology. 2015 Apr 28;84(17):1732-8
pubmed: 25832661
Age Ageing. 1989 Nov;18(6):371-9
pubmed: 2629484
J Ment Health. 2016;25(2):137-41
pubmed: 26361062
Restor Neurol Neurosci. 2015;33(5):727-40
pubmed: 26444639
Neurology. 1989 May;39(5):638-43
pubmed: 2710353
JAMA Psychiatry. 2016 Oct 1;73(10):1032-1040
pubmed: 27603000
J Clin Epidemiol. 1989;42(8):703-9
pubmed: 2760661
J Phys Ther Sci. 2016 Aug;28(8):2253-9
pubmed: 27630408
Psychiatry Investig. 2016 Nov;13(6):659-664
pubmed: 27909458
Clin Drug Investig. 2017 Oct;37(10):901-928
pubmed: 28756557
Ann Neurol. 2018 Mar;83(3):612-622
pubmed: 29451321
Psychiatry Investig. 2018 Feb;15(2):141-146
pubmed: 29475223
J Psychiatry Neurosci. 2018 Mar;43(2):76-78
pubmed: 29481314
Medicine (Baltimore). 2018 Jun;97(23):e10919
pubmed: 29879031
Stat Methods Med Res. 2019 Aug;28(8):2455-2474
pubmed: 29966490
J Stroke Cerebrovasc Dis. 2018 Nov;27(11):3208-3211
pubmed: 30078760
Psychol Med. 2019 Mar;49(4):685-696
pubmed: 30107864
Front Psychiatry. 2018 Nov 01;9:530
pubmed: 30443225
Neurosci Biobehav Rev. 2019 Jan;96:182-196
pubmed: 30465786
Lancet. 2019 Jan 19;393(10168):265-274
pubmed: 30528472
Stroke. 1988 May;19(5):547-54
pubmed: 3363586
Stroke. 1986 Nov-Dec;17(6):1102-7
pubmed: 3810708
Arch Phys Med Rehabil. 1994 Aug;75(8):852-7
pubmed: 8053790
Stroke. 1994 Feb;25(2):346-51
pubmed: 8303743
Int Psychogeriatr. 1995 Winter;7(4):547-60
pubmed: 8833278